SynthesisThe Cochrane database of systematic reviews2011
Interventions for rosacea.
Synthesis in The Cochrane database of systematic reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.The British journal of dermatology · 2019Pooled it
- Interventions for rosacea.The Cochrane database of systematic reviews · 2015Pooled it
- Trial
- The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications.Postepy dermatologii i alergologii · 2023Review
- Shotgun metagenomic sequencing reveals skin microbial variability from different facial sites.Frontiers in microbiology · 2022Article
- Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS).The Journal of clinical and aesthetic dermatology · 2020Article
- Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel.The British journal of dermatology · 2020Article
- Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.American health & drug benefits · 2018Article
- Towards a better understanding of the therapeutic applications and corresponding mechanisms of action of honey.Environmental science and pollution research international · 2017Review
- Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.Patient preference and adherence · 2017Review
- Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.Journal of managed care & specialty pharmacy · 2016Article
- The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis.SpringerPlus · 2016Article
- The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review.Clinical reviews in allergy & immunology · 2015Review
- Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea.American health & drug benefits · 2015Article
- The role of brimonidine tartrate gel in the treatment of rosacea.Clinical, cosmetic and investigational dermatology · 2015Review
- Orphan diseases of the nose and paranasal sinuses: Pathogenesis - clinic - therapy.GMS current topics in otorhinolaryngology, head and neck surgery · 2015Review
- Preliminary open-label clinical evaluation of the soothing and reepithelialization properties of a novel topical formulation for rosacea.Clinical, cosmetic and investigational dermatology · 2014Article
- The Cochrane Skin Group: a vanguard for developing and promoting evidence-based dermatology.Journal of evidence-based medicine · 2013Article
- The effect of pulsed dye laser on the dermatology life quality index in erythematotelangiectatic rosacea patients: an assessment.The Journal of clinical and aesthetic dermatology · 2013Article
- Effects of a facial cream containing the minor alkaloid anatabine on improving the appearance of the skin in mild to moderate rosacea: an open-label case series study.Case reports in dermatology · 2013Article
Corrections and comments
- Updated by
- Update of
Authors and funding
5 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRosacea is a common chronic skin condition affecting the face, characterised by flushing, redness, pimples, pustules, and dilated blood vessels. The eyes are often involved and thickening of the skin with enlargement (phymas), especially of the nose, can occur in some patients. A range of treatment options are available but it is unclear which are the most effective.
objectivesTo assess the evidence for the efficacy and safety of treatments for rosacea. SEARCH STRATEGY: In February 2011 we updated our searches of the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (Clinical Trials) in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index, and Ongoing Trials Registers. SELECTION CRITERIA: Randomised controlled trials in people with moderate to severe rosacea. DATA COLLECTION AND ANALYSIS: Study selection, data extraction, assessment of risk of bias, and analyses were carried out by two independent review authors. MAIN
resultsFifty-eight trials, including 27 from the original review, comprising 6633 participants were included in this updated review. Interventions included topical metronidazole, oral antibiotics, topical azelaic cream or gel, topical benzoyl peroxide and/or combined with topical antibiotics, sulphacetamide/sulphur, and others. Only two studies assessed our primary outcome 'quality of life'.Pooled data from physician assessments in three trials provided some evidence that metronidazole was more effective compared to placebo (RR 1.95, 95% CI 1.48 to 2.56). Three trials provided data, based on participants' assessments, illustrating azelaic acid was more effective than placebo (RR 1.52, 95% CI 1.32 to 1.76).Physician-based assessments in two trials indicated that doxycycline appeared to be significantly more effective than placebo (RR 1.59, 95% CI 1.02 to 2.47 and RR 2.37, 95% CI 1.12 to 4.99). There was no statistically significant difference in effectiveness between 100 mg and 40 mg doses of doxycycline, but there was evidence of less adverse effects with the lower dose (RR 0.25, 95% CI 0.11 to 0.54).One study reported that cyclosporine ophthalmic emulsion was significantly more effective than artificial tears for treating ocular rosacea (for all outcomes). AUTHORS'
conclusionsAlthough the majority of included studies were assessed as being at high or unclear risk of bias there was some evidence to support the effectiveness of topical metronidazole, azelaic acid, and doxycycline (40 mg) in the treatment of moderate to severe rosacea, and cyclosporine 0.5% ophthalmic emulsion for ocular rosacea. Further well-designed, adequately-powered randomised controlled trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.